News
Evolva statement to SER communication
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
Pfizer Inc. (NYSE:PFE) today announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
Granite Declares Quarterly Dividend
Granite Construction Incorporated (NYSE: GVA) today announced that its Board of Directors has declared a quarterly cash dividend of $0.13 per common share. The dividend is payable on January 13
State Street Global Advisors Announces Share Splits for Four SPDR® ETFs
State Street Global Advisors, the asset management business of State Street Corporation (NYSE: STT), today announced share splits on four SPDR ETFs. The splits will decrease the funds’ share prices
Albany International Increases Dividend
The Board of Directors of Albany International Corp. (NYSE: AIN) today declared a quarterly dividend of $0.25 per share on the Company’s Class A Common Stock, an increase of 19% over the prior
Essex Property Trust Declares Quarterly Distributions
Essex Property Trust, Inc. (NYSE:ESS) announced today that its Board of Directors has declared a regular quarterly cash dividend of $2.20 per common share, payable January 13, 2023 to shareholders
Fuller, Smith & Turner PLC: Transaction in Own Shares
CI Financial Named a Top Employer for 2023
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) has been named one of Greater Toronto’s Top Employers for 2023, an award that recognizes firms with progressive human resources practices and
Pfizer Declares First-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.41 for the first-quarter 2023 dividend
Travis Perkins: Director/PDMR Shareholding
Rights and Issues Investment Trust PLC: Transaction in Own Shares
EQS-Adhoc: va-Q-tec AG: Prospectively near-term conclusion of a Business Combination Agreement with EQT Private Equity and approval of a cash capital increase without subscription rights of approx. 10%
RPM to Announce Fiscal 2023 Second Quarter Results on January 5, 2023
RPM International Inc. (NYSE: RPM) announced today that it will release its financial results for the fiscal 2023 second quarter before the stock market opens on Thursday, January 5, 2023. The
Fifth Third offers tips on how to keep your money, credit and identity safe during the holiday shopping season
The rise of online and mobile banking and electronic financial transactions have made life easier for consumers. However, without proper security measures, they can put you at risk for fraud and
Victory Capital Reports November 2022 Assets Under Management
Victory Capital Holdings, Inc. (NASDAQ: VCTR) (“Victory Capital” or the “Company”) today reported assets under management (AUM) of $161.5 billion as of November 30, 2022. The Company also reported
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: RPS Group plc
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in